The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The Globe and Mail has
updated our Stock Quote Pages
You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

 

GW Pharmaceuticals PLC

Nasdaq: GWPH
Last

(U.S.) $122.84

Today's change+3.44 +2.88%
Updated June 30 4:00 PM -4GMT. Delayed by at least 15 minutes.
 

GW Pharmaceuticals PLC

Nasdaq: GWPH
Last

(U.S.) $122.84

Today's change+3.44 +2.88%
Updated June 30 4:00 PM -4GMT. Delayed by at least 15 minutes.

GW Pharmaceuticals PLC up sharply

GW Pharmaceuticals PLC closed up sharply Tuesday, rallying (U.S.)$3.44 or 2.88% to (U.S.)$122.84. Shares have lost 3.47% over the last five days, but have gained 81.50% over the last year to date. This security has outperformed the S&P 500 by 9.25% during the last year.

Key company metrics

  • Open(U.S.) $121.42
  • Previous close(U.S.) $119.40
  • High(U.S.) $123.29
  • Low(U.S.) $120.85
  • Bid / Ask-- / --
  • YTD % change+81.50%
  • Volume298,176
  • Average volume (10-day)369,701
  • Average volume (1-month)374,707
  • Average volume (3-month)454,877
  • 52-week range(U.S.) $58.16 to (U.S.) $133.98
  • Beta--
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$1.33
Updated June 30 4:00 PM -4GMT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-49.95%

Although this company's net profit margin is negative, it is above the industry average and implies that GW Pharmaceuticals PLC is operating more effectively than other companies in the industry.
Company Books

S&P TSX0.44%Sector:Industry:
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q1/2015Q4/2014Q3/2014Q2/2014
Fiscal Quarter Endvalues in $ millions unless otherwise notedDec 31, 201412/31/2014Sep 30, 201409/30/2014Jun 30, 201406/30/2014Mar 31, 201403/31/2014
Revenue87815
Total other revenue--------
Total revenue87815
Gross profit77714
Total cost of revenue1011
Total operating expense1291526
Selling / general / administrative1044
Research & development15121021
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income-4-2-7-11
Interest income (expense), net non-operating0000
Gain (loss) on sale of assets--------
Other--------
Income before tax-4-2-7-11
Income after tax-30-7-8
Income tax, total-1-20-3
Net income-30-7-8
Total adjustments to net income--------
Net income before extra. items-30-7-8
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-30-7-8
Inc. avail. to common incl. extra. items-30-7-8
Diluted net income-30-7-8
Dilution adjustment0000
Diluted weighted average shares237237218194
Diluted EPS excluding extraordinary itemsvalue per share-0.010.00-0.03-0.04
Dividends per sharevalue per share0.00--0.000.00
Diluted normalized EPSvalue per share-0.010.00-0.03-0.04